Media

Tesla BioHealing and Cell Biotechnology Co., Ltd. Forge Strategic Partnership to Transform Stem Cell Therapies
Butler, PA / AccessWire / September 11, 2024 — Tesla BioHealing-PA, LLC, a leader in biophoton life force technology, and Cell Biotechnology Co., Ltd, an innovator in stem cell transplantation, have entered a strategic collaboration to revolutionize the development and delivery of stem cell therapies. This partnership, effective September 9, 2024, unites the companies' groundbreaking technologies to significantly enhance patient outcomes by empowering autologous stem cell amplification and ensuring immediate availability of large numbers of stem cells.

For more details, please read the full press release here.


New Clinical Study Shows Biophoton Generators Aid in Cognitive Recovery for Alzheimer's Patients

Philadelphia, PA, July 27, 2024 — A new clinical study presented at the Alzheimer’s Association International Conference (AAIC) reveals that biophoton generators significantly improve cognitive functions and quality of life for individuals with moderate to severe Alzheimer's disease. The study, led by Dr. Mariola Smotrys at the First Institute of All Medicines, shows promising results in enhancing memory, orientation, functional ability, and overall life quality for Alzheimer’s patients.

For more details, please read the full press release here.


Clinical Studies Highlight the Potential of Tesla BioHealing Biophoton Generator in Improving Mobility for Chronic Stroke Patients

Butler, PA, July 24, 2024 --(PR.com)-- The First Institute of All Medicines recently completed a randomized, double-blind, and placebo-controlled clinical study to evaluate the effectiveness of the Tesla BioHealing® Biophoton Generator in 42 chronic stroke patients.

The results of the study suggest that the Tesla BioHealing® Biophoton Generator may significantly enhance mobility in patients with chronic stroke conditions, marking a notable advancement in addressing the long-term disabilities caused by strokes.

For more details, please read the full press release here.